Results 141 to 150 of about 4,127 (170)

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Nuclear Medicine and Molecular Imaging, 2021
Liver tumors, both primary and secondary to metastatic disease, remain a major challenge, with an increasing incidence. In this context, taking advantage of the dual blood supply of the liver, and the fact that liver tumors derive majority of their blood supply from the hepatic artery, intraarterial therapies are gaining popularity. Intraarterial liver-
Aysheh, Alrfooh, Aditi, Patel, Sandeep, Laroia   +2 more
openaire   +2 more sources

Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients

Frontiers in Oncology, 2023
IntroductionAlthough transarterial radioembolization (TARE) using yttrium-90 (90Y) is a treatment option for large hepatocellular carcinoma (HCC), a fraction of patients are ineligible for TARE due to high lung shunt fraction (LSF).MethodsWe evaluated if treatment with transarterial chemoembolization (TACE), owing to TARE ineligibility was associated ...
Jeong-Hoon Lee, Hyo-Cheol Kim, Jin Chul Paeng   +2 more
exaly   +5 more sources

Transarterial Radioembolization (TARE)

2018
Transarterial radioembolization (TARE) refers to the delivery of radioactive microspheres directly into an artery that perfuses a tumor or tumor-bearing tissue. In current clinical practice, radioembolization is employed almost exclusively for liver tumors, which include primary liver tumors such as hepatocellular carcinoma, as well as metastatic ...
Ryan Hickey, Robert J. Lewandowski, Riad Salem   +2 more
openaire   +1 more source

Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma

Abdominal Radiology, 2021
Transarterial radioembolization with yttrium-90 microspheres is an established therapy for hepatocellular carcinoma. Post-procedural imaging is important for the assessment of both treatment response and procedural complications. A variety of challenging treatment-specific imaging phenomena complicate imaging assessment, such as changes in tumoral size,
Zersenay Alem, Timothy E. Murray, Csilla Egri, John Chung, David Liu, Khaled M. Elsayes, Silvia D. Chang, Alison Harris   +7 more
openaire   +2 more sources

Transarterial Radioembolization: Patient Selection and Microsphere Characteristics

Digestive Disease Interventions, 2021
AbstractTransarterial radioembolization (TARE) using yttrium-90 (90Y)-labeled microspheres has become increasingly adopted as an important treatment option for primary and metastatic hepatic malignancies. Rigorous patient evaluation and selection prior to TARE is critical to optimize the benefits of this therapy and minimize adverse events.
openaire   +1 more source

Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma

American Journal of Gastroenterology, 2023
INTRODUCTION: The efficacy and safety of combined immunotherapy and transarterial radioembolization (TARE) were suggested in preclinical and early-phase trials, but these were limited by small sample sizes. We sought to compare the efficacy of combined therapy and immunotherapy alone in patients with advanced hepatocellular ...
Yee Hui Yeo, Jeff Liang, Marie Lauzon, Michael Luu, Mazen Noureddin, Walid Ayoub, Alexander Kuo, Kamya Sankar, Jun Gong, Andrew Hendifar, Arsen Osipov, Marc L. Friedman, H. Gabriel Lipshutz, Jonathan Steinberger, Kambiz Kosari, Nicholas Nissen, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang   +18 more
openaire   +2 more sources

[Transarterial radioembolization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma].

Der Radiologe, 2022
Since the first version of the S3 guideline for the diagnosis and treatment of hepatocellular carcinoma (HCC) in 2013, a large number of studies have consolidated the data on transarterial radioembolization (TARE) and created a broad evidence base.
Thomas, Helmberger, Philippe L, Pereira
openaire   +1 more source

Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma

Abdominal Radiology, 2017
To assess the radiopathologic correlation following Yttrium-90 transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) using variable radiodosimetry to identify imaging surrogates of histologic response.Twelve patients with HCC underwent ablative (≥ 190 Gy) and/or non-ablative (
Altan F. Ahmed, Naziya Samreen, Joseph R. Grajo, Ivan Zendejas, Chris L. Sistrom, Amy Collinsworth, Ashwini Esnakula, Jehan L. Shah, Roniel Cabrera, Brian S. Geller, Beau B. Toskich   +10 more
openaire   +2 more sources

Bilioenteric Fistula following Segmental Transarterial Radioembolization

Journal of Vascular and Interventional Radiology, 2021
Manish Patel, Brian Funaki, Thuong Van Ha, Steven Zangan, Helen Te, Osman Ahmed   +5 more
openaire   +2 more sources

[Transarterial radioembolization : Immune effects and immuno-oncology].

Der Radiologe, 2020
Transarterial radioembolization (TARE) is a locoregional minimally invasive therapeutic strategy to treat primary and secondary hepatic neoplasia.The objective was to assess TARE-induced immuno-oncological effects and its perspective for potential therapy improvement by using a combinatory strategy with immune checkpoint inhibitors (ICI).Yttrium-90 ...
Borna, Relja, Maciej, Pech
openaire   +1 more source